2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertinib + Chemo vs. Osimertinib Alone for Advanced EGFRm Disease

526 views
February 23, 2024
Disclaimer: On February 16, 2024, the FDA approved osimertinib (TAGRISSO®) with platinum-based chemotherapy for patients with la/mNSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
0 Comments
Login to view comments. Click here to Login